06268391 is referenced by 48 patents and cites 5 patents.

Compounds of general formula (I) wherein: R

1

is H or optionally joined with R

2

to form a fused ring selected from the group consisting of five to ten membered aryl, heteroaryl or heterocyclyl rings, R

2

and R

3

are independently H, HET, aryl, C

1-12

aliphatic, CN, NO

2

, halogen, R

10

, —OR

10

, —SR

10

, —S(O)R

10

, —SO

2

R

10

, —NR

10

R

11

, —NR

11

R

12

, —NR

12

COR

11

, —NR

12

CO

2

R

11

, —NR

12

CONR

11

R

12

, —NO

12

SO

2

R

11

, —NR

12

C(NR

12

)NHR

11

, —COR

11

, —CO

2

R

11

, —CONR

12

R

11

, —SO

2

NR

12

R

11

, —OCONR

12

R

11

, C(NR

12

)NR

12

R

11

, R

6

and R

7

are independently halogen, CN, NO

2

, —CONR

10

R

11

, —SO

2

NR

10

R

11

, —NR

10

R

11

, or —OR

11

, where R

10

and R

11

are as defined below; R

8

is OH, NHSO

2

R

12

or NHCOCF

3

; and their use in therapy, especially in the treatment of disorders mediated by cRaf1 kinase.

Title
Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases
Application Number
9/446586
Publication Number
6268391 (B1)
Application Date
April 7, 2000
Publication Date
July 31, 2001
Inventor
James Marvin Veal
Apex
NC, US
Michael Robert Peel
Chapel Hill
NC, US
Robert Walton McNutt Jr
Durham
NC, US
Karen Elizabeth Lackey
Hillsborough
NC, US
David Kendall Jung
Durham
NC, US
Robert Neil Hunter III
Raleigh
NC, US
Philip Anthony Harris
Raleigh
NC, US
Scott Howard Dickerson
Chapel Hill
NC, US
Agent
John L Lemanowicz
US
Assignee
Glaxo Wellcome
NC, US
IPC
A61K 31/404
View Original Source